Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.BO)
INR 688.55
(0.19%)
INR 688.55
(0.19%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 424.96 Million | 466.55 Million | 69.14 Million | 282.22 Million | 118.85 Million | 308.98 Million |
| Net Income | 224.63 Million | 348.08 Million | 266.42 Million | 218.72 Million | 94.14 Million | 90.02 Million |
| Depreciation & Amortization | 16.62 Million | 11.75 Million | 15.26 Million | 10.86 Million | 11.29 Million | 10.15 Million |
| Deferred income taxes | 7.07 Million | -49.54 Million | - | - | - | - |
| Stock-based compensation | 133.1 Million | 87.65 Million | - | - | - | - |
| Change in working capital | 55.39 Million | 98.76 Million | -114.55 Million | 115.94 Million | 48.38 Million | 197.1 Million |
| Other non-cash items | 99.68 Million | -30.15 Million | -97.99 Million | -63.3 Million | -34.97 Million | 11.69 Million |
| Investing Cash Flow | -319.15 Million | -576.71 Million | -257.79 Million | -22.64 Million | -110.73 Million | -8.25 Million |
| Investments in PPE | -2.48 Million | -3.18 Million | -10.49 Million | -4.69 Million | -18.54 Million | -22.54 Million |
| Acquisitions | - | 12.96 Million | 5.81 Million | - | - | 22.54 Million |
| Investment purchases | -1.35 Billion | -1.03 Billion | -284.48 Million | -41.72 Million | -113.86 Million | - |
| Sales/Maturities of investments | 1.03 Billion | 412.19 Million | - | - | - | - |
| Other Investing Activities | -243 Million | 34.28 Million | 31.37 Million | 23.77 Million | 21.68 Million | -8.25 Million |
| Financing Cash Flow | -88.74 Million | -4.57 Million | -175.52 Million | -68.28 Million | -18.24 Million | -60.5 Million |
| Debt repayment | -6.33 Million | -3.22 Million | -67.88 Million | - | -8.79 Million | -45.15 Million |
| Dividends payments | -130.99 Million | - | -104.79 Million | -26.2 Million | -13.1 Million | -6.55 Million |
| Common Stock Repurchased | - | - | - | -36.94 Million | - | - |
| Common Stock Issuance | 56.35 Million | - | - | - | - | - |
| Other Financing Activities | 48.21 Million | -4.57 Million | -2.85 Million | -5.13 Million | -5.14 Million | -8.8 Million |
| Accounts receivables | 91.54 Million | -55.56 Million | -29.55 Million | 87.89 Million | -7.03 Million | 44.03 Million |
| Accounts payables | -89.82 Million | -19.62 Million | -10.75 Million | 63.4 Million | -1.51 Million | 27.67 Million |
| Inventory | 53.1 Million | 90.66 Million | -180 Thousand | -3.99 Million | 33.67 Million | 187.41 Million |
| Other working capital | 570 Thousand | 83.28 Million | -74.07 Million | -31.36 Million | 23.24 Million | -62.02 Million |
| Cash at beginning of period | 110.53 Million | 225.26 Million | 589.43 Million | 398.13 Million | 408.24 Million | 145.12 Million |
| Cash at end of period | 1.47 Billion | 110.53 Million | 225.26 Million | 589.42 Million | 398.13 Million | 385.34 Million |
| Capital Expenditure | -2.48 Million | -3.18 Million | -10.49 Million | -4.69 Million | -18.54 Million | -22.54 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 1.36 Billion | -114.73 Million | -364.17 Million | 191.29 Million | -10.11 Million | 240.22 Million |
| Free Cash Flow | 422.48 Million | 463.37 Million | 58.65 Million | 277.53 Million | 100.3 Million | 286.43 Million |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 53.29 Million | 35.49 Million | 224.63 Million | 39.63 Million | 74.72 Million | 74.79 Million |
| Depreciation & Amortization | - | - | 16.62 Million | 4.12 Million | 4.55 Million | 3.93 Million |
| Deferred income taxes | - | - | 7.07 Million | - | - | - |
| Stock-based compensation | 24.25 Million | 22.74 Million | 133.1 Million | 26.52 Million | 41.81 Million | 42.03 Million |
| Change in working capital | - | - | 55.39 Million | - | - | - |
| Other non-cash items | -77.54 Million | -58.23 Million | 99.68 Million | -66.15 Million | -116.53 Million | -116.82 Million |
| Investing Cash Flow | - | - | -319.15 Million | - | - | - |
| Investments in PPE | - | - | -2.48 Million | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | -1.35 Billion | - | - | - |
| Sales/Maturities of investments | - | - | 1.03 Billion | - | - | - |
| Other Investing Activities | - | - | -243 Million | - | - | - |
| Financing Cash Flow | - | - | -88.74 Million | - | - | - |
| Debt repayment | - | - | -6.33 Million | - | - | - |
| Dividends payments | - | - | -130.99 Million | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 56.35 Million | - | - | - |
| Other Financing Activities | - | - | 48.21 Million | - | - | - |
| Accounts receivables | - | - | 91.54 Million | - | - | - |
| Accounts payables | - | - | -89.82 Million | - | - | - |
| Inventory | - | - | 53.1 Million | - | - | - |
| Other working capital | - | - | 570 Thousand | - | - | - |
| Cash at beginning of period | - | - | 110.53 Million | 1.11 Billion | 1.04 Billion | 110.53 Million |
| Cash at end of period | - | - | 1.47 Billion | 39.63 Million | 1.11 Billion | 74.79 Million |
| Capital Expenditure | - | - | -2.48 Million | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | 1.36 Billion | -1.07 Billion | 74.72 Million | -35.74 Million |
| Free Cash Flow | - | - | 422.48 Million | 39.63 Million | 74.72 Million | 74.79 Million |
6262
WEWIN
IG6
INNOCORP
PLLTL
SEMAC